MX347343B - Proteinas de fusion de fragmentos de proteinas humanas naturales para crear composiciones de fc de inmunoglobulinas multimerizadas ordenadamente. - Google Patents

Proteinas de fusion de fragmentos de proteinas humanas naturales para crear composiciones de fc de inmunoglobulinas multimerizadas ordenadamente.

Info

Publication number
MX347343B
MX347343B MX2013001148A MX2013001148A MX347343B MX 347343 B MX347343 B MX 347343B MX 2013001148 A MX2013001148 A MX 2013001148A MX 2013001148 A MX2013001148 A MX 2013001148A MX 347343 B MX347343 B MX 347343B
Authority
MX
Mexico
Prior art keywords
fusion proteins
immunoglobulin
compositions
human protein
protein fragments
Prior art date
Application number
MX2013001148A
Other languages
English (en)
Other versions
MX2013001148A (es
Inventor
S Block David
Olsen Henrik
Original Assignee
Gliknik Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gliknik Inc filed Critical Gliknik Inc
Publication of MX2013001148A publication Critical patent/MX2013001148A/es
Publication of MX347343B publication Critical patent/MX347343B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención se refiere a un dímero o multímero de orden superior de un compuesto, caracterizado porque: el compuesto comprende un dominio Fc de IgG1 directamente unido en su terminal carboxilo a un dominio de multimerización en donde dicho dominio de multimerización es un dominio bisagra de IgG2, y en donde el monómero de domino Fc de IgG1 comprende una primera secuencia de polipéptido de SEQ ID NO: 2; y en donde cada uno de los monómeros de domino bisagra de IgG2 comprende una segunda secuencia de polipéptido de SEQ ID NO: 3, en donde dicha segunda secuencia de polipéptido está directamente unida al terminal carboxilo de la primera secuencia de polipéptido, y en donde el dímero o multímero de orden superior es capaz de unirse al menos a dos receptores Fc? (Fc?R).
MX2013001148A 2010-07-28 2011-07-28 Proteinas de fusion de fragmentos de proteinas humanas naturales para crear composiciones de fc de inmunoglobulinas multimerizadas ordenadamente. MX347343B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36846510P 2010-07-28 2010-07-28
PCT/US2011/045768 WO2012016073A2 (en) 2010-07-28 2011-07-28 Fusion proteins of natural human protein fragments to create orderly multimerized immunoglobulin fc compositions

Publications (2)

Publication Number Publication Date
MX2013001148A MX2013001148A (es) 2014-02-27
MX347343B true MX347343B (es) 2017-04-21

Family

ID=45530725

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2016009799A MX368531B (es) 2010-07-28 2011-07-28 Proteinas de fusion de fragmentos de proteinas humanas naturales para crear composiciones de fc de inmunoglobulinas multimerizadas ordenadamente.
MX2013001148A MX347343B (es) 2010-07-28 2011-07-28 Proteinas de fusion de fragmentos de proteinas humanas naturales para crear composiciones de fc de inmunoglobulinas multimerizadas ordenadamente.
MX2019012016A MX2019012016A (es) 2010-07-28 2013-01-28 Proteinas de fusion de fragmentos de proteinas humanas naturales para crear composiciones de fc de inmunoglobulinas multimerizadas ordenadamente.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2016009799A MX368531B (es) 2010-07-28 2011-07-28 Proteinas de fusion de fragmentos de proteinas humanas naturales para crear composiciones de fc de inmunoglobulinas multimerizadas ordenadamente.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2019012016A MX2019012016A (es) 2010-07-28 2013-01-28 Proteinas de fusion de fragmentos de proteinas humanas naturales para crear composiciones de fc de inmunoglobulinas multimerizadas ordenadamente.

Country Status (21)

Country Link
US (3) US20130156765A1 (es)
EP (2) EP2598533B1 (es)
JP (2) JP5826270B2 (es)
KR (3) KR20200111213A (es)
CN (2) CN103154036B (es)
AR (1) AR082404A1 (es)
AU (1) AU2011282579B2 (es)
BR (1) BR112013002074B1 (es)
CA (2) CA2804512C (es)
DK (1) DK2598533T3 (es)
ES (1) ES2719623T3 (es)
HR (1) HRP20190652T1 (es)
HU (1) HUE044869T2 (es)
IL (3) IL224427A (es)
MX (3) MX368531B (es)
PL (1) PL2598533T3 (es)
PT (1) PT2598533T (es)
SI (1) SI2598533T1 (es)
TR (1) TR201906652T4 (es)
TW (2) TWI588157B (es)
WO (1) WO2012016073A2 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107011445B (zh) 2007-06-01 2021-06-29 马里兰大学巴尔的摩分校 免疫球蛋白恒定区Fc受体结合剂
WO2010065578A2 (en) * 2008-12-04 2010-06-10 Leukosight Inc. POLYPEPTIDES COMPRISING Fc FRAGMENTS OF IMMUNOGLOBULIN G (IgG) AND METHODS OF USING THE SAME
DK2598533T3 (en) 2010-07-28 2019-04-23 Gliknik Inc Fusion proteins of natural human protein fragments to create in an orderly fashion multimerized immunoglobulin FC compositions
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
BR112015003459A2 (pt) * 2012-08-20 2017-09-26 Gliknik Inc moléculas com atividade de ligação ao antígeno e de ligação ao receptor fc gama polivalente
CN104870055A (zh) * 2012-10-17 2015-08-26 利物浦热带医学院 免疫调节蛋白
WO2014168715A1 (en) * 2013-04-08 2014-10-16 R-Pharm Overseas, Inc. B7 ligands/cd20 inhibitor composition and use thereof
WO2015069745A2 (en) * 2013-11-05 2015-05-14 The Board Of Regents Of The University Of Texas System Tumors expressing igg1 fc induce robust cd8 cell responses
US10745463B2 (en) 2013-11-18 2020-08-18 University Of Maryland, Baltimore Hyper-glycosylated antibodies with selective Fc receptor binding
US9725710B2 (en) 2014-01-08 2017-08-08 Flodesign Sonics, Inc. Acoustophoresis device with dual acoustophoretic chamber
SG11201606597QA (en) 2014-03-05 2016-09-29 Ucb Biopharma Sprl Multimeric fc proteins
SG11201607070VA (en) 2014-05-02 2016-11-29 Momenta Pharmaceuticals Inc Compositions and methods related to engineered fc constructs
US20180044416A1 (en) * 2015-03-05 2018-02-15 Ucb Biopharma Sprl Polymeric Fc proteins and methods of screening to alter their functional characteristics
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
KR20240042137A (ko) * 2015-07-24 2024-04-01 글리크닉 인코포레이티드 향상된 상보체 결합을 갖는 규칙적으로 다형체화된 면역글로불린 fc 조성물을 생성하기 위한 인간 단백질 단편의 융합 단백질
WO2017172853A1 (en) 2016-03-30 2017-10-05 Ab Biosciences, Inc. Recombinant intravenous immunoglobulin (rivig) compositions and methods for their production and use
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
CN109963869A (zh) 2016-05-23 2019-07-02 动量制药公司 与经改造的Fc构建体相关的组合物和方法
EP3464347B1 (en) * 2016-06-07 2023-05-31 Gliknik Inc. Cysteine-optimized stradomers
CN109641048A (zh) * 2016-07-22 2019-04-16 格利克尼克股份有限公司 产生具有增强的Fc受体结合的经有序多聚化的免疫球蛋白Fc组合物的人蛋白片段的融合蛋白
BR112019009495A2 (pt) * 2016-12-09 2019-08-06 Gliknik Inc métodos de tratamento de distúrbios inflamatórios com compostos de fc multivalentes
CN110177802A (zh) 2016-12-09 2019-08-27 格利克尼克股份有限公司 多聚化stradomer GL-2045的制造优化
BR112019013955A2 (pt) 2017-01-06 2020-02-11 Momenta Pharmaceuticals, Inc. Composições e métodos relacionados a construtos de fc manipulados
CN114900773A (zh) 2017-12-14 2022-08-12 弗洛设计声能学公司 声泳系统及其操作方法、控制声换能器及声学系统的方法
CN112004550A (zh) 2017-12-14 2020-11-27 康诺贝林伦瑙有限公司 用于治疗视神经脊髓炎的重组IgG Fc多聚体
US20220332847A1 (en) 2019-09-13 2022-10-20 CSL Behring Lengnau AG RECOMBINANT IgG Fc MULTIMERS FOR THE TREATMENT OF IMMUNE COMPLEX-MEDIATED KIDNEY DISORDERS
US20230242672A1 (en) * 2020-06-25 2023-08-03 Gliknik Inc. Ace2-fc fusion proteins and methods of use
KR20230061710A (ko) * 2021-10-29 2023-05-09 주식회사 이뮤노로지컬디자이닝랩 Cadm1을 인식하는 재조합 단백질 및 이를 유효성분으로 포함하는 암의 치료용 약학적 조성물

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6004781A (en) 1988-01-22 1999-12-21 The General Hospital Corporation Nucleic acid encoding Ig-CD4 fusion proteins
GB8824869D0 (en) 1988-10-24 1988-11-30 Stevenson G T Synthetic antibody
US5681566A (en) 1988-10-24 1997-10-28 3I Research Exploitation Limited Antibody conjugates with two or more covalently linked FC regions
US5336616A (en) 1990-09-12 1994-08-09 Lifecell Corporation Method for processing and preserving collagen-based tissues for transplantation
ES2109362T3 (es) 1991-06-21 1998-01-16 Univ Cincinnati Unas proteinas administrables oralmente y metodo para hacerlas.
IL102915A (en) 1992-01-19 2005-12-18 Yeda Res & Dev Soluble ldl receptor and its preparation
WO1994003191A1 (en) 1992-08-07 1994-02-17 Progenics Pharmaceuticals, Inc. NON-PEPTIDYL MOIETY-CONJUGATED CD4-GAMMA2 AND CD4-IgG2 IMMUNOCONJUGATES, AND USES THEREOF
EP0680337A4 (en) 1993-01-12 1997-07-30 Anthony George Gristina METHODS AND COMPOSITIONS FOR DIRECT APPLICATION WITH HIGH CONCENTRATION OF ANTIBODIES, PRODUCING PASSIVE IMMUNITY.
US5877396A (en) 1993-04-23 1999-03-02 Sloan Kettering Institute For Cancer Research Mice mutant for functional Fc receptors and method of treating autoimmune diseases
US6750334B1 (en) 1996-02-02 2004-06-15 Repligen Corporation CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
US20020147326A1 (en) 1996-06-14 2002-10-10 Smithkline Beecham Corporation Hexameric fusion proteins and uses therefor
AU3871099A (en) 1998-05-06 1999-11-23 Temple University - Of The Commonwealth System Of Higher Education Reversal of proinflammatory response by ligating the macrophage fcgammari receptor
US7250494B2 (en) 1998-06-15 2007-07-31 Biosynexus Incorporated Opsonic monoclonal and chimeric antibodies specific for lipoteichoic acid of Gram positive bacteria
US6933326B1 (en) 1998-06-19 2005-08-23 Lifecell Coporation Particulate acellular tissue matrix
AU770555B2 (en) 1998-08-17 2004-02-26 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
EP1248645B1 (en) 2000-01-03 2007-04-18 Tr Associates, L.L.C. Novel chimeric proteins and their use
EP1349569B1 (en) 2001-01-12 2007-04-18 Becton Dickinson and Company Intrinsically fluorescent, self-multimerizing mhc fusion proteins and complexes thereof
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
AU2002241922B2 (en) 2001-01-17 2007-10-25 Aptevo Research And Development Llc Binding domain-immunoglobulin fusion proteins
ES2393733T3 (es) 2001-03-07 2012-12-27 Merck Patent Gmbh Tecnología de expresión para proteínas que contienen una fracción de anticuerpo de isotipo híbrido
US7511121B2 (en) * 2001-03-09 2009-03-31 Arnason Barry G W Polymeric immunoglobulin fusion proteins that target low-affinity Fcγreceptors
US7282556B2 (en) 2001-05-15 2007-10-16 Emory University Polynucleotides and polypeptides relating to the modulation of SIRPα-CD47
KR100453877B1 (ko) 2001-07-26 2004-10-20 메덱스젠 주식회사 연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 ＴＮＦＲ/Ｆｃ 융합 단백질, 상기 단백질을 코딩하는 ＤＮＡ, 상기 ＤＮＡ를 포함하는벡터, 및 상기 벡터에 의한 형질전환체
KR100938989B1 (ko) 2001-12-18 2010-01-28 다우 코닝 도레이 캄파니 리미티드 광경화성 유기 중합체 조성물
AU2003217912A1 (en) * 2002-03-01 2003-09-16 Xencor Antibody optimization
AU2003253621A1 (en) 2002-06-14 2003-12-31 Centocor, Inc. Modified "s" antibodies
CA2505601C (en) 2002-11-15 2014-10-28 Musc Foundation For Research Development Complement receptor 2 targeted complement modulators
AU2004204817C1 (en) 2003-01-13 2011-01-20 Macrogenics, Inc. Soluble FcyR fusion proteins and methods of use thereof
PL1606318T3 (pl) 2003-03-26 2010-01-29 Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts Ulepszone białka fuzyjne FC
US7348004B2 (en) 2003-05-06 2008-03-25 Syntonix Pharmaceuticals, Inc. Immunoglobulin chimeric monomer-dimer hybrids
WO2005007809A2 (en) 2003-05-30 2005-01-27 Alexion Pharmaceuticals, Inc. Antibodies and fusion proteins that include engineered constant regions
WO2005005604A2 (en) 2003-06-30 2005-01-20 Centocor, Inc. Engineered anti-target immunoglobulin derived proteins, compositions, methods and uses
EP1691832A2 (en) 2003-09-29 2006-08-23 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Immunoglobulins whith potent and broad antiviral activity
ATE522548T1 (de) 2003-11-13 2011-09-15 Hanmi Holdings Co Ltd Verfahren zur massenproduktion der konstanten region von immunglobulin
EP1697520A2 (en) 2003-12-22 2006-09-06 Xencor, Inc. Fc polypeptides with novel fc ligand binding sites
WO2005089503A2 (en) 2004-03-19 2005-09-29 Progenics Pharmaceuticals, Inc. Cd4-igg2 formulations
US20090232867A1 (en) 2004-07-19 2009-09-17 Elutex Ltd. Modified conductive surfaces having active substances attached thereto
EP1824979A2 (en) 2004-12-10 2007-08-29 Trigen GmbH Methods, products and uses involving platelets and/or the vasculature
CA2605401A1 (en) 2005-04-19 2006-10-26 University Of Maryland Compositions and methods for modulating interleukin-10
ES2427646T5 (es) 2005-05-09 2017-08-22 Ono Pharmaceutical Co., Ltd. Anticuerpos monoclonales humanos contra muerte programada 1 (PD1) y métodos para el tratamiento del cáncer mediante el uso de anticuerpos anti-PD-1 solos o combinados con otros agentes inmunoterapéuticos
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
CN101258164B (zh) 2005-08-16 2013-05-01 韩美科学株式会社 用于大量生产缺失起始甲硫氨酸残基的免疫球蛋白Fc区的方法
US7666622B2 (en) 2005-10-19 2010-02-23 Regeneron Pharmaceuticals, Inc. Monomeric self-associating fusion polypeptides and therapeutic uses thereof
US8211852B2 (en) 2006-02-17 2012-07-03 Rappaport Family Institute For Research In The Medical Sciences Molecules and methods of using same for treating CCR5/CCR5 ligands associated diseases
WO2007100083A1 (ja) 2006-03-03 2007-09-07 Tokyo University Of Science 生物活性を強化した抗体改変体
CA3149553C (en) 2006-06-12 2023-11-21 Aptevo Research And Development Llc Single-chain multivalent binding proteins with effector function
AT503889B1 (de) 2006-07-05 2011-12-15 Star Biotechnologische Forschungs Und Entwicklungsges M B H F Multivalente immunglobuline
GB0614780D0 (en) 2006-07-25 2006-09-06 Ucb Sa Biological products
US20080260738A1 (en) 2007-04-18 2008-10-23 Moore Margaret D Single chain fc, methods of making and methods of treatment
ES2471915T3 (es) 2007-05-11 2014-06-27 Alexion Pharma Holding Fosfatasa alcalina dirigida al hueso, kits y métodos de uso de la misma
CN101802197A (zh) 2007-05-14 2010-08-11 比奥根艾迪克Ma公司 单链FC（ScFc）区、包含其的结合多肽及与其相关的方法
CA2693053C (en) * 2007-05-30 2021-01-05 Xencor, Inc. Methods and compositions for inhibiting cd32b expressing cells
CN107011445B (zh) 2007-06-01 2021-06-29 马里兰大学巴尔的摩分校 免疫球蛋白恒定区Fc受体结合剂
JP5706688B2 (ja) 2007-06-14 2015-04-22 ギャラクティカ ファーマシューティカルズ， インク． Ｒａｇｅ融合タンパク質
BRPI0817108B8 (pt) 2007-09-21 2021-05-25 Univ California composição compreendendo uma proteína de fusão, kit compreendendo a referida composição e uso da mesma.
US20090104210A1 (en) 2007-10-17 2009-04-23 Tota Michael R Peptide compounds for treating obesity and insulin resistance
DK2222697T3 (da) 2007-11-01 2013-03-11 Perseid Therapeutics Llc Immunsuppressive polypeptider og nukleinsyrer
WO2010065578A2 (en) 2008-12-04 2010-06-10 Leukosight Inc. POLYPEPTIDES COMPRISING Fc FRAGMENTS OF IMMUNOGLOBULIN G (IgG) AND METHODS OF USING THE SAME
JP5876416B2 (ja) 2009-11-13 2016-03-02 グリフオルス・セラピユーテイクス・インコーポレーテツドＧｒｉｆｏｌｓ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． フォンウィルブランド因子（ｖＷＦ）含有調製品並びにこれに関連する方法、キット及び使用
GB0922209D0 (en) 2009-12-18 2010-02-03 Univ Nottingham Proteins, nucleic acid molecules and compositions
AU2011272941B2 (en) 2010-06-30 2014-05-29 Compugen Ltd. C10RF32 for the treatment of multiple sclerosis, rheumatoid arthritis and other autoimmune disorders
DK2598533T3 (en) 2010-07-28 2019-04-23 Gliknik Inc Fusion proteins of natural human protein fragments to create in an orderly fashion multimerized immunoglobulin FC compositions
CA2899433A1 (en) 2012-01-27 2013-08-01 Gliknik Inc. Fusion proteins comprising igg2 hinge domains
BR112015003459A2 (pt) 2012-08-20 2017-09-26 Gliknik Inc moléculas com atividade de ligação ao antígeno e de ligação ao receptor fc gama polivalente
US20180282424A1 (en) 2014-11-06 2018-10-04 Gliknik Inc. Molecules with bimodal activity depleting target at low dose and increasing immunosuppression at higher dose

Also Published As

Publication number Publication date
KR20180050429A (ko) 2018-05-14
BR112013002074A2 (pt) 2016-05-24
US20180002388A1 (en) 2018-01-04
CA2804512C (en) 2015-11-24
AU2011282579B2 (en) 2014-10-23
CA2804512A1 (en) 2012-02-02
CN103154036A (zh) 2013-06-12
KR102148265B1 (ko) 2020-08-26
IL254796A0 (en) 2017-12-31
CN103154036B (zh) 2016-05-11
MX2019012016A (es) 2019-11-11
TWI542597B (zh) 2016-07-21
JP6225142B2 (ja) 2017-11-01
JP2015227346A (ja) 2015-12-17
MX368531B (es) 2019-10-07
TWI588157B (zh) 2017-06-21
PL2598533T3 (pl) 2019-07-31
DK2598533T3 (en) 2019-04-23
HUE044869T2 (hu) 2019-12-30
US20130156765A1 (en) 2013-06-20
EP2598533B1 (en) 2019-02-20
EP3543257A1 (en) 2019-09-25
AR082404A1 (es) 2012-12-05
PT2598533T (pt) 2019-05-08
JP5826270B2 (ja) 2015-12-02
KR20200111213A (ko) 2020-09-28
US20220056087A1 (en) 2022-02-24
IL224427A (en) 2017-10-31
CA2902942C (en) 2020-12-22
US11117940B2 (en) 2021-09-14
KR102066996B1 (ko) 2020-01-17
EP2598533A4 (en) 2015-08-05
BR112013002074B1 (pt) 2021-09-14
AU2011282579A1 (en) 2013-01-24
CA2902942A1 (en) 2012-02-02
SI2598533T1 (sl) 2019-05-31
JP2013543483A (ja) 2013-12-05
TR201906652T4 (tr) 2019-05-21
CN105820256A (zh) 2016-08-03
WO2012016073A2 (en) 2012-02-02
TW201207104A (en) 2012-02-16
EP2598533A2 (en) 2013-06-05
IL268724B (en) 2022-05-01
MX2013001148A (es) 2014-02-27
HRP20190652T1 (hr) 2019-05-31
IL268724A (en) 2019-10-31
ES2719623T3 (es) 2019-07-11
WO2012016073A3 (en) 2012-08-09
IL254796B (en) 2019-09-26
TW201706313A (zh) 2017-02-16
KR20130043171A (ko) 2013-04-29

Similar Documents

Publication Publication Date Title
MX2019012016A (es) Proteinas de fusion de fragmentos de proteinas humanas naturales para crear composiciones de fc de inmunoglobulinas multimerizadas ordenadamente.
MX2022008337A (es) Proteinas de fusion de fragmentos de proteina humana para crear composiciones de fc de inmunoglobulina multimerizada de forma ordenada con union al complemento aumentada.
MX2018013738A (es) Anticuerpos que comprenden dominios constantes quimericos.
MX2012007318A (es) Proteina de fusion de la region constante del anticuerpo-cd47 tetravalente para usarse en terapia.
GB2450056A (en) CD47 Related compositions and methods for treating immunological diseases and disorders
ECSP099683A (es) Proteinas de union incluyendo anticuerpos, derivados de anticuerpos y fragmentos de anticuerpos que se unen especificamente a cd154 y sus usos.
EP2352523A4 (en) IMPROVED ANTI-CD19 ANTIBODIES
MX348071B (es) Variantes de fc.
AU2013211824A8 (en) Fusion proteins comprising IgG2 hinge domains
MX2014001883A (es) Proteinas y peptidos modificados.
EA201400568A1 (ru) Альбуминсвязывающие антитела и их связывающие фрагменты
GB201112429D0 (en) Antigen-binding proteins with increased FcRn binding
MA34004B1 (fr) Protéines de liaison à cd127
SG10201805411YA (en) Chimeric antigen receptors
EA030777B9 (ru) Анти-альфа-синуклеинсвязывающие молекулы
WO2010003766A3 (en) Multimeric tnf receptors
MX2010006767A (es) Anticuerpos de virus de hepatitis c.
EA201290525A1 (ru) Новые антитела-антагонисты, их fab-фрагменты против gpvi и способы их применения
UA108778C2 (xx) Протираковий злитий протеїн
NZ760789A (en) Uti fusion proteins
MX2019000887A (es) Proteínas de fusión de fragmentos de proteínas humanas para crear composiciones de fc de inmunoglobina multimerizadas en un orden con unión mejorada al receptor de fc.
NZ750009A (en) Antibodies comprising chimeric constant domains

Legal Events

Date Code Title Description
FG Grant or registration